• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

A rapid LC-MS/MS quantification of peramivir using a simple and inexpensive sample precipitation: application to PK

tetano

Editor, Senior Moderator
Bioanalysis. 2015 Feb;7(3):319-32. doi: 10.4155/bio.14.248.
[h=1]A rapid LC-MS/MS quantification of peramivir using a simple and inexpensive sample precipitation: application to PK.[/h] Wang ZZ[SUP]1[/SUP], Zhang M, Shang DW, Ni XJ, Hu JQ, Qiu C, Wen YG.
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]AIM:[/h] Peramivir is a newly approved selective neuraminidase inhibitor designed to inhibit influenza virus infection.
[h=4]METHODOLOGY/RESULTS:[/h] We report a robust and sensitive method utilizing simple precipitation extraction with LC-MS/MS for the high-throughput quantification. Addition of 0.06 M of ammonium formate and 0.1% formic acid in mobile phase could help reduce the matrix effect. This method uses 100 ?l of plasma and covers a linear concentration range from 5 to 10,000 ng/ml. Other validation parameters are also evaluated and meet regulatory expectations by US FDA guidelines.
[h=4]CONCLUSION:[/h] The developed HPLC-MS/MS method has been successfully applied to support a clinical pharmacokinetic study. The strategy presented here can be applied elsewhere and may be useful for other amphiphilic drugs.


PMID: 25697190 [PubMed - in process]
 
Back
Top Bottom